Gilead acquired the rights to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, the Philippines, Vietnam, Thailand, Malaysia and Mongolia. In mainland China and Singapore, the drug is approved for therapy of inoperable breast cancer. Regulators in Hong Kong, South Korea and Taiwan continue to review applications. Gilead will make an upfront payment of $280 million and will pay another $175 million when certain regulatory and commercial targets are met.